JAK2 V617F Inhibitors
1 drugsAbout JAK2 V617F
JAK2 V617F is a mutated form of the Janus kinase 2 (JAK2) protein, a tyrosine kinase crucial for hematopoiesis. The V617F mutation leads to constitutive activation of the JAK-STAT signaling pathway, driving uncontrolled cell proliferation.
The direct link between the JAK2 V617F mutation and disease pathogenesis makes it a compelling therapeutic target in myeloproliferative neoplasms. There is currently no genetic evidence data available for this specific target.
JAK2 V617F is targeted by one FDA-approved drug, OJJAARA (GSK), a small molecule with two indications. GSK is the only company with an approved drug for this target.
Top JAK2 V617F Drugs
GSK is the only company with an approved drug targeting JAK2 V617F.
The market is highly concentrated, suggesting high barriers to entry or limited innovation.
JAK2 V617F Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets JAK2 V617F, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
JAK2 V617F Clinical Trials 19 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on JAK2 V617F. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 1 | 0 | 5 | 100% |
| Phase 2 | 8 | 2 | 1 | 5 | 67% |
| Phase 3 | 4 | 3 | 1 | 0 | 75% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
JAK2 V617F Drug Approval Timeline (2023 - 2023)
The first and only drug, OJJAARA, was approved in 2023.
Recent approval suggests potential for further drug development and market growth.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 9 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on JAK2 V617F. A trial counts if an approved drug acting on JAK2 V617F is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.